To further confirm whether MLT degraded AML1‐ETO protein in primary leukemic samples, BM leukaemia blasts from two AML patients carrying AML1‐ETO were treated with MLT for 24 and 48 hours. The gene discussed is RUNX1T1; the disease is leukemia.